Compare
Indivior Pharmaceuticals, Inc. vs Prestige Consumer Healthcare Inc. vs Alkermes plc. vs Phibro Animal Health Corp
| Latest fiscal year | Indivior Pharmaceuticals, Inc. INDV | Prestige Consumer Healthcare Inc. PBH | Alkermes plc. ALKS | Phibro Animal Health Corp PAHC |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2026-03-31 | 2025-12-31 | 2026-06-30 |
| Revenue | $1.24B | $1.09B | $1.48B | $1.52B |
| Revenue growth (YoY) | +4.3% | -4.3% | -5.2% | +17.1% |
| Gross margin | 80.2% | 54.7% | 86.7% (computed) | 33.8% |
| Operating margin | 21.1% | 28.4% | 17.2% | 12.8% |
| Net margin | 16.9% | 17.5% | 16.4% | 6.6% |
| Net income | $210.00M | $190.30M | $241.66M | $99.72M |
| EPS (Diluted) | $1.64 | $3.91 | $1.43 | $2.43 |
| Operating cash flow | -$27.00M | $257.63M | $520.75M | $68.95M |
| Free cash flow | -$93.00M | $246.45M | $480.33M | $9.87M |
| Cash & equivalents | $195.00M | $63.87M | $388.57M | $61.42M |
| Total assets | $1.20B | $3.49B | $2.49B | $1.50B |
| Total liabilities | $1.30B | $1.61B | $667.70M | $1.12B |
| Shareholders' equity | -$98.00M | $1.89B | $1.82B | $385.48M |
| Return on year-end equity | n/a | 10.1% | 13.3% | 25.9% |
| Shares outstanding | n/a | n/a | 165.61M | n/a |
Revenue, most recent five fiscal years
| Fiscal year | Indivior Pharmaceuticals, Inc. | Prestige Consumer Healthcare Inc. | Alkermes plc. | Phibro Animal Health Corp |
|---|---|---|---|---|
| Latest | $1.24B Ended 2025-12-31 | $1.09B Ended 2026-03-31 | $1.48B Ended 2025-12-31 | $1.52B Ended 2026-06-30 |
| 1 year earlier | $1.19B Ended 2024-12-31 | $1.14B Ended 2025-03-31 | $1.56B Ended 2024-12-31 | $1.30B Ended 2025-06-30 |
| 2 years earlier | $1.09B Ended 2023-12-31 | $1.13B Ended 2024-03-31 | $1.66B Ended 2023-12-31 | $1.02B Ended 2024-06-30 |
| 3 years earlier | $901.00M Ended 2022-12-31 | $1.13B Ended 2023-03-31 | $1.11B Ended 2022-12-31 | $977.89M Ended 2023-06-30 |
| 4 years earlier | n/a | $1.09B Ended 2022-03-31 | $1.17B Ended 2021-12-31 | $942.26M Ended 2022-06-30 |